1. Home
  2. RGEN vs NCLH Comparison

RGEN vs NCLH Comparison

Compare RGEN & NCLH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RGEN
  • NCLH
  • Stock Information
  • Founded
  • RGEN 1981
  • NCLH 1966
  • Country
  • RGEN United States
  • NCLH United States
  • Employees
  • RGEN N/A
  • NCLH N/A
  • Industry
  • RGEN Medical/Dental Instruments
  • NCLH Marine Transportation
  • Sector
  • RGEN Health Care
  • NCLH Consumer Discretionary
  • Exchange
  • RGEN Nasdaq
  • NCLH Nasdaq
  • Market Cap
  • RGEN 6.5B
  • NCLH 11.5B
  • IPO Year
  • RGEN N/A
  • NCLH 2013
  • Fundamental
  • Price
  • RGEN $119.39
  • NCLH $25.40
  • Analyst Decision
  • RGEN Buy
  • NCLH Buy
  • Analyst Count
  • RGEN 10
  • NCLH 19
  • Target Price
  • RGEN $163.78
  • NCLH $28.33
  • AVG Volume (30 Days)
  • RGEN 718.1K
  • NCLH 16.7M
  • Earning Date
  • RGEN 11-11-2025
  • NCLH 10-30-2025
  • Dividend Yield
  • RGEN N/A
  • NCLH N/A
  • EPS Growth
  • RGEN N/A
  • NCLH 61.59
  • EPS
  • RGEN N/A
  • NCLH 1.54
  • Revenue
  • RGEN $673,956,000.00
  • NCLH $9,560,994,000.00
  • Revenue This Year
  • RGEN $16.79
  • NCLH $8.19
  • Revenue Next Year
  • RGEN $13.68
  • NCLH $10.51
  • P/E Ratio
  • RGEN N/A
  • NCLH $16.55
  • Revenue Growth
  • RGEN 8.73
  • NCLH 5.22
  • 52 Week Low
  • RGEN $102.97
  • NCLH $14.21
  • 52 Week High
  • RGEN $182.52
  • NCLH $29.29
  • Technical
  • Relative Strength Index (RSI)
  • RGEN 49.56
  • NCLH 52.73
  • Support Level
  • RGEN $112.73
  • NCLH $25.06
  • Resistance Level
  • RGEN $122.71
  • NCLH $27.18
  • Average True Range (ATR)
  • RGEN 4.85
  • NCLH 0.91
  • MACD
  • RGEN -0.27
  • NCLH -0.03
  • Stochastic Oscillator
  • RGEN 53.02
  • NCLH 44.89

About RGEN Repligen Corporation

Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 58% of 2024 revenue, while chromatography, proteins, and process analytics were 19%, 12%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.

About NCLH Norwegian Cruise Line Holdings Ltd.

Norwegian Cruise Line is the world's third-largest publicly traded cruise company by berths (around 71,000). It operates 34 ships across three brands—Norwegian, Oceania, and Regent Seven Seas—offering both freestyle and luxury cruising. The company redeployed its entire fleet as of May 2022. With 13 passenger vessels on order among its brands through 2036, representing 38,400 incremental berths, Norwegian is increasing capacity faster than its peers, expanding its brand globally. Norwegian sails to around 700 global destinations.

Share on Social Networks: